Biotech Archives - Page 102 of 795

1 minute read

Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data At Keystone Symposia On Systemic Autoimmune and Autoinflammatory Diseases

February 12, 9:31 AM

The poster presentation includes the first description of Corvus' next-generation ITK inhibitor preclinical product candidates, which were designed to deliver precise T-cell modulation that is optimized for specific

CRVS

1 minute read

Aspira Women’s Health Announces Late-Breaking Poster Presentation At The Upcoming 71st Annual Scientific Meeting For The Society For Reproductive Investigation

By Benzinga Newsdesk

February 12, 9:15 AM

Aspira Women's Health Inc. ("Aspira") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced a late-breaking poster presentation at

AWH

4 minute read

4DMT Presents Interim Data From 4D-310 INGLAXA Phase 1/2 Clinical Trials For Fabry Disease Cardiomyopathy At WORLDSymposium 2024

By Benzinga Newsdesk

February 12, 9:10 AM

4D-310 demonstrated clinically meaningful cardiac endpoint improvements through 12-24 months in contractility (echocardiography), peak VO2 (cardiopulmonary exercise testing) and/or cardiac quality of life (KCCQ) in all

FDMT

3 minute read

FDA Approves Takeda’s EOHILIA, The First And Only Oral Treatment In The U.S. For Eosinophilic Esophagitis

By Benzinga Newsdesk

February 12, 9:00 AM

— 12 Weeks of Treatment with EOHILIA May Address Significant Unmet Needs of Patients 11 Years of Age and Older— EoE Is a Chronic Disease That Can Significantly Impact Patients, with Esophageal Inflammation and

TAK

1 minute read

RBC Capital’s Rating Upgrade Propels IGM Biosciences Into Immunology Limelight

By Vandana Singh

February 9, 3:16 PM

IGM Biosciences' strategic shift to immunology with promising bispecific drug, imvotamab. RBC Capital upgraded stock to Outperform, anticipating $21 price target. Data expected in 2H 2024 validates its potential in lupus and rheumatoid arthritis.

IGMS

2 minute read

Why Is Moderna Stock Trading Lower Today?

By Vandana Singh

February 9, 1:03 PM

Moderna long term data indicates a faster decline in efficacy for its RSV vaccine than the RSV vaccines from GSK and Pfizer.

GSK

2 minute read

Good News For Sleep Disorder Patients – Takeda’s Therapy Shows Promise In Mid-Stage Study

By Vandana Singh

February 9, 12:45 PM

Takeda's Phase 2b trial results for TAK-861, an oral orexin receptor 2 agonist, in narcolepsy type 1 patients. Global Phase 3 trials planned for fiscal year 2024.

TAK

2 minute read

Rare Disease Focused-Synlogic Pulls Plug On Lead Program, Shares Nosedive

By Vandana Singh

February 9, 11:53 AM

Synlogic discontinues Synpheny-3 study for PKU treatment. Explore strategic options as CEO Dr. Aoife Brennan departs.

SYBX

1 minute read

Evoke Pharma Has Priced An Underwritten Public Offering Led By Nantahala Capital Management For Gross Proceeds Of Up To $30M Million, Which Includes Initial Upfront Funding Of Approximately $7.5M

By Benzinga Newsdesk

February 9, 8:33 AM

The offering is comprised of (i) 11,029,411 shares of common stock (or pre-funded warrants in lieu thereof), (ii) 11,029,411 Series A Warrants with an initial exercise price of $0.68 per share and a term of

EVOK

3 minute read

Masimo Announces New Peer-Reviewed Study Finds That Masimo SET Pulse Oximetry Measures Accurately Across The Skin Tone Range Even During Low Perfusion

By Benzinga Newsdesk

February 8, 5:51 PM

Masimo (NASDAQ:MASI) today announced the findings of a retrospective, peer-reviewed study published in the Journal of Clinical Monitoring and Computing in which Dr. Vikrant Sharma, along with Dr. Steven J. Barker, Dr.

MASI